latest update:
[TrialBase DB]

trial summary · NCT06340633

SPI-1005 in Adults Receiving Cochlear Implant

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SPI-1005 in Adults Receiving a Cochlear Implant

Trial record from the TrialBase DB dataset, status RECRUITING, condition Hearing Loss, sponsored by Sound Pharmaceuticals, Incorporated. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT06340633phase PHASE2enrollment 40start 2026-12

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The goal of this clinical trial is to learn about the effects of drug SPI-1005 in adults receiving a cochlear implant with a long electrode array (FLEX26 or greater) from MED-EL Cochlear Implant Systems into one ear. The main question this clinical trial aims to answer is: Is drug SPI-1005 safe and well-tolerated in adults receiving a cochlear implant, and/or what medical problems might participants experience when taking drug SPI-1005? The clinical trial will also measure the effects of SPI-1005 on hearing, word recognition, speech discrimination, tinnitus, and vertigo outcomes after receiving a cochlear implant. The purpose for this and future clinical trials is to learn whether SPI-1005 can prevent or treat these side effects after receiving a cochlear implant. Participants will take drug SPI-1005 or placebo (a look-alike substance that contains no drug) for 6 months, starting 2 days before receiving the cochlear implant. There are 5 required in-clinic visits over 6 months for audiology and other tests. The effects of SPI-1005 will be compared to the placebo (the look-alike substance that contains no drug) to study what effects SPI-1005 might have.

Source record: https://clinicaltrials.gov/study/NCT06340633

Facts

registry idNCT06340633
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionHearing Loss
sponsorSound Pharmaceuticals, Incorporated
sponsor classINDUSTRY
enrollment40
start date2026-12
primary completion2026-12
completion2026-12
results postednot reported

Conditions

  • Hearing Loss
  • Cochlear Trauma

Interventions

  • Ebselen
  • Placebo

Countries

  • United States

Intervention types: DRUG

Work with this record